RE: Merry Christmas All22 Dec 2023 22:51
M Schmainda LinkedIn. “A tremendously active year by the trial team with significant milestones achieved! Two Orphan Drug Designations: GBM - GBM (pediatric and adult) and ATRT brain tumors, and now this Fast Track Designation. Not to mention the fantastic and on-going momentum of the phase 1 trial. Congrats to all - a great way to close out 2023 and usher in 2024!”